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The analysis of circulating tumour cells (CTCs) in cancer patients could provide important information for
therapeutic management. Enrichment of viable CTCs could permit performance of functional analyses on
CTCs to broaden understanding of metastatic disease. However, this has not been widely accomplished.
Addressing this challenge, we present a separable bilayer (SB)microfilter for viable size-based CTC capture.
Unlike other single-layer CTC microfilters, the precise gap between the two layers and the architecture of
pore alignment result in drastic reduction in mechanical stress on CTCs, capturing them viably. Using
multiple cancer cell lines spiked in healthy donor blood, the SB microfilter demonstrated high capture
efficiency (78–83%), high retention of cell viability (71–74%), high tumour cell enrichment against
leukocytes (1.7–23 103), andwidespread ability to establish cultures post-capture (100% of cell lines tested).
In a metastatic mouse model, SB microfilters successfully enriched viable mouse CTCs from 0.4–0.6 mL
wholemouse blood samples and established in vitro cultures for further genetic and functional analysis. Our
preliminary studies reflect the efficacy of the SB microfilter device to efficiently and reliably enrich viable
CTCs in animal model studies, constituting an exciting technology for new insights in cancer research.
M
etastatic disease represents the ability of solid tumour cells to intravasate from their site of origin, travel
through the haematogenous and/or lymphatic circulatory systems and extravasate at distant secondary
sites where new tumours are colonized. In contrast to early stage disease, treatment strategies in the
metastatic setting are largely palliative rather than curable, where over 90% of cancer-related mortality can be
attributed to disease outgrowth beyond the primary site1. To improve the survival rates among late stage and
recurrent cancer patients, 1) enhanced diagnostic tools for earlier detection, 2) treatment monitoring strategies
that detect the underlying cellular and molecular changes arising from selective pressure posed by the treatment
process, and 3) therapies that better target the metastatic cells directly are in urgent need.
Numerous studies suggest circulating tumour cells (CTCs), the tumour subpopulation responsible for invasion
and colonization of distant sites, to be a candidate biomarker for prognosis, diagnosis and treatment monitoring
of metastatic disease2–5. Assaying for CTCs requires only a simple, minimally invasive blood draw, providing a
unique opportunity for repeated sampling in patients to monitor both metastatic disease as well as therapeutic
response in real-time. Although promising for their diagnostic and prognostic potential, detecting and analysing
CTCs is thwarted by their paucity, with only a few tumour cells occurring among billions of non-tumour cells in
peripheral blood4,6. Thus highly efficient enrichment strategies are a prerequisite and a technical limitation for
CTC analysis7.
In recent years, a number of CTC enrichment systems have been developed8,9. Immunological approaches
depend on cell surface antigen expression10–12. Epithelial cell surface markers expressed predominantly on CTCs,
such as epithelial cell adhesion molecule (EpCAM), are widely used13–23. The CellSearchH system represents the
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most prominently used platform by this approached, which enriches
CTCs from whole blood using an EpCAM-based immunomagnetic
separation process24–26. Currently, it is the only FDA cleared clinical
CTC analysis system for metastatic breast, prostate and colorectal
cancers. In addition to immunological approaches, unique physical
properties of cancer cells have also been exploited for CTC enrich-
ment, including cell size, deformability, electrical and acoustic
properties18,27–31.
Beyond the enumeration andmolecular characterization of CTCs,
the development of the enrichment of viable CTCs enables their
functional characterization that are critical for disease interrogation
and target therapy32–34. Viable CTCs in metastatic breast cancer have
been enriched using multi-marker FACS technology, where in one
study a metastasis-initiating subpopulation of primary luminal
breast cancer CTCs were used to generate a mouse xenograft model
that gives rise to bone, lung and brain metastases29. In another study,
a microfluidic device combined live CTC capture and ‘‘on-chip’’
treatment with taxol drugs to demonstrate microtubule organization
alterations in CTCs35.
Our group has previously described the development of a 2D
round pore-shaped microfilter fabricated on a single 10 mm-thick
parylene-C membrane by photolithography36. Pre-fixation of blood
samples are needed to prevent cell lysis during filtration, which
makes it unusable for viable CTC enrichment. To alleviate this lim-
itation, we developed a 3D membrane microfilter, where blood sam-
ples are processed for CTC enrichment with no prior fixation37.
While we demonstrated an ability to capture viable tumour cells in
model systems, trapping of cells inside of the pores restricts cell
proliferation and cell release.
Herein, we report the new design of a separable bilayer (SB)micro-
filter. The SBmicrofilter has fundamentally different device structure
and filtration principles. These improvements have significantly
enhanced our ability to enrich and characterize viable CTCs. We
evaluated the performance of the SB microfilter device using both
in vitro and in vivo systems, where we demonstrate (1) high sensitiv-
ity and efficiency of viable tumour cell capture, (2) the ability to
enrich tumour cells from multiple types of cancer cell lines for their
proliferation directly on the surface of the microfilter or on second-
ary culture surfaces, (3) the ability to enrich viable CTCs in a breast
cancer mouse model system for subsequent cell culture and func-
tional characterization, and (4) the ability to enrich viable CTCs from
a clinical blood sample. The SB microfilter is a new, high perform-
ance viable CTC enrichment device with the potential to have
important utility in both research and clinical applications.
Results
Design and operation of the SB microfilter. In the SB microfilter,
the capture is realized by the gap between the top and bottom porous
membranes (Figure 1A). They were made from biocompatible
polymer parylene-C aiming to better preserve the viability of the
cells. A 3D view in Figure 1B summarizes the geometrical design
parameters. The bottom layer contains the 8 mm diameter holes
arranged hexagonally. Larger holes of 40 mm diameter were
created on the top parylene-C layer and aligned to the centres of
the corresponding hexagon patterns on the bottom layer. An
example elemental unit after fabrication is shown in Figure 1C.
Each elemental unit is encoded by dots at the top left corner of the
unit on the bottom parylene-C layer as an index to facilitate the
identification and positioning of captured cells of interest.
The operation of the SB microfilter was first demonstrated using
healthy blood samples spiked with tumour cell line. GFP expressing
MCF-7 cells (green fluorescent) were spiked in whole blood and
passed through the SB microfilter. An example of the microfilter
following filtration is shown in Figure 2A&B. The majority of the
captured tumour cells were located along the edges of the large top
pores, although tumour cells could partially or completely wedge into
the gap between the top and bottom parylene-C layers.
After the tumour cells are captured on the SB microfilters, it is
possible to separate the top and bottom parylene-C membranes to
access the captured cells. Figure 2C shows the concept and
Figure 1 | Device design. (A): Cartoon of device cross-sectional view showing tumour cells are captured along the edges of the large top parylene-C pores;
(B): 3D view of an elemental unit model with key geometrical parameters labelled, including the gap distance in inset; (C): Microscopic picture of
top view of an elemental unit showing large pores on top parylene-C layer and small pores on bottom parylene-C layer with index dots on the top left
corner. Scale bar is 100 mm.
www.nature.com/scientificreports
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Figure 2D–2G demonstrates an example using MDA-MB-231 cells
labelled with long-term fluorescence cell tracer carboxyfluorescein
diacetate, succinimidyl ester (CFDA-SE, Invitrogen CA). After cell
capture, two pairs of tweezers were used to hold the edges of the top
and bottom parylene-Cmembrane respectively.Withminimal force,
the two layers could be separated. The separable feature of the device
is controlled by engineering the adhesion strength between the
top and bottom parylene-C layers during microfabrication. In
Figure 2E–2G, the majority of captured cells were maintained on
the bottom parylene-C layer at their original positions after the sepa-
ration of the two parylene-C membranes. Uncompromised green
fluorescent intensity of the captured cells indicated that the cell viab-
ility was preserved during the separation.
Characterization of the SB microfilter. There are multiple
performance parameters for CTC enrichment, including capture
efficiency, enrichment, cell viability, blood sample capacity and
processing speed. Often, some of these parameters are inversely
related to each other. As a result, optimization requires achieving a
compromise depending on specific downstream applications. The SB
microfilter was tested with tumour cell lines spiked in DPBS, healthy
human blood, blood from animal cancer models, and clinical blood
samples.
The capture efficiency and enrichment were measured using two
breast cancer cell lines: MCF-7, estrogen receptor and progesterone
receptor (ER/PR) positive and less invasive; and MDA-MB-231, tri-
ple negative and highly invasive. The measured capture efficiencies
were 83 6 3% for MCF-7 and 78 6 4% for MDA-MB-231 (n 5 4
each) when ,130 cells in ,1 mL of DPBS were spiked in 1 mL of
DPBS (Figure 3A). Assuming perfect capture efficiency, enrichment
can be uncoupled from capture efficiency and measured indepen-
dently38. The enrichment was thus determined by the retention of
non-tumour leukocytes. The ratio of leukocytes inside the original
blood sample and those left on the device was used as measured
enrichment against leukocytes. The measured enrichment factors
were 2.0 6 0.3 3 103 for MCF-7 and 1.7 6 0.4 3 103 for MDA-
MB-231 (Figure 3B). The measured capture efficiency and enrich-
ment factors are comparable to the previous 3D microfilters with
similar double layer membrane structure37.
Cell viability after captured on SB microfilters. An important
feature of the SB microfilter is its capability for viable cell
enrichment. In contrast to the 2D pore-shaped microfilter, the SB
microfilter is capable of processing unfixed and undiluted whole
blood samples. This not only eliminates sample manipulation steps
before filtration, but more importantly enables downstream
applications that require the viability of cells. Two approaches
were employed to study cell viability after enrichment. First, the
viability of MCF-7 and MDA-MB-231 cancer cells after filtration
were determined with the LIVE/DEAD viability assay using
Figure 2 | Demonstration of the operation of the SBmicrofilter. (A)–(B): Representative areas of the SBmicrofilter after filtration. MCF-7 breast cancer
cells were GFP-expressing (A) while surrounding blood cells could also be seen in bright field/fluorescence composite view (B). Scale bars are 50 mm.
(C)–(G): The top and bottom parylene-C membrane layers can be separated after cell enrichment. (C): Image showing the concept of separable
microfilter. (D): MDA-MB-231 cells labelled with CFDA-SE. (E): Cells captured on SB microfilter before separation of the top and bottom parylene-C
layers. (F): The bottom parylene-C layer after separation. (G): The top parylene-C layer after separation. Scale bars are 100 mm.
www.nature.com/scientificreports
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Calcein-AM green and Ethidium Homodimer-1 (EthD-1). Calcein-
AM green is a permeable fluorogenic esterase substrate that reacts
with cells containing active enzyme activity, thus labelling viable cells
with green fluorescence, while impermeable DNAbinding dye EthD-
1 only reaches the nucleus when the plasma membrane has been
compromised or destroyed, thus labelling dead cells with red
fluorescence. An example of such on-chip LIVE/DEAD analysis is
shown in Figure 3C–3F. Cell viability is defined as the ratio of live
cells versus total cells on themicrofilter after the filtration. Each assay
was repeated four times for each cell line. The calculated cell viability
was 746 2% forMCF-7 and 71 6 9% forMDA-MB-231 cancer cells
(Figure 3G). As a control, the viability assay was also performed on
tumour cells that weren’t passed through the SB microfilter. Instead
of using the microfilter, cell counting was carried out on a glass
microscope slide. The calculated viability was 95 6 3% from
triplicate control samples (data not shown).
In the second approach to demonstrate cell viability after filtra-
tion, wild adenovirus type 5 was modified with green fluorescence
expression gene eGFP under the control of CMV promoter. It has
been shown that modified adenovirus can preferably infect and
express in tumour cells and thus can be used as a tool for viable
CTC detection39. In this experiment, MCF-7 cells weremodified with
a red fluorescence expressingmCherry gene. As shown in Figure 4H–
4K, cells with both red and green fluorescence (mCherry1GFP1)
represented virus-infected viable MCF-7 cells, while cells with only
red fluorescence (mCherry1GFP2) are presumably non-viable cells.
The virus infection assay probed the cell’s ability to actively express
proteins (GFP in this case). Therefore, it is a different viability indi-
cator compared with the measurement of membrane permeability
(EthD-1) and enzyme activity (Calcein-AM). It should be noted that,
assigning all themCherry1GFP2 as non-viable tumour cells made an
assumption that the efficiency of virus infection and GFP expression
in viable tumour cells was 100%. Based on the initial test, the virus
infection efficiencywasmeasured to be 90%, 95%depending on the
tumour cell lines (data not shown).
Cell proliferation following capture by the SB microfilters. To
investigate whether captured tumour cells can proliferate directly
on the SB microfilters, tumour cells from various cell lines
(DU145, Hela, LnCaP and PC3) were spiked in DPBS and
captured on SB microfilters, respectively. The SB microfilters were
placed individually in a six-well plate and cultured as using standard
Figure 3 | Characterization of device performance. (A): Capture efficiency is measured and plotted for two cell lines, MCF-7 andMDA-MB-231 human
breast cancer cell lines. Each column shows the mean value and its standard deviation (n 5 4). (B): Enrichment factor from undiluted human blood is
measured and plotted. Each column shows themean value and its standard deviation (n5 4). (C)–(G): LIVE/DEAD assay with representative areas of the
SB microfilter after filtration. Viable MDA-MB-231 cancer cells are highlighted with green (C) while dead tumour cells are in red (D). Fluorescence
composite (E) and differential interference contrast (DIC)/fluorescence composite (F) of tumour cells detected in A and B. LIVE/DEAD cell assay
consisting of viable cell indicator Calcein-AM green and the exclusion dye Ethidium Homodimer-1 were used. (G): Cell viability after filtration is
measured and plotted for two cell lines, MCF-7 and MDA-MB-231 human breast cancer cell lines. Each column shows the mean value and its standard
deviation (n 5 4). (H)–(K): Cell viability detected by virus infection. The mCherry-expressing MCF-7 cells were used. Infected viable cancer cells
expressed green fluorescence protein. The capturedMCF-7 cancer cells were highlighted with red (H) while infected viable tumour cells were in green (I).
Fluorescence composite image (J) and differential interference contrast (DIC) image overlaid with fluorescence composite image (K) of tumour cells
detected in (A) and (B). Scale bars are 10 mm.
www.nature.com/scientificreports
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conditions of the particular cell lines. As shown in Figure 4, captured
tumour cells grew into colonies on day 4 following filtration and large
patches of confluency were observed by day 8. The morphology of
cells and the shape of colonies shared similarity with that of the
parental cells growing under the standard conditions. It is
encouraging to observe that following SB microfilter enrichment,
captured tumour cells can proliferate directly on-chip, a critical
step forward towards CTC culture from clinical blood samples.
Demonstration of SB microfilter performance in mouse model
systems. Primary tumours were established in 100% (6/6) of mice
injected, and in vitro cell cultures from each primary tumour
digested were successfully established in all cases. Cell cultures
were established from blood samples in 33% (1/3) of mice injected
with 4T1 and 4T07 cells, respectively, demonstrating SBmicrofilter’s
ability to permit tumour cell expansion directly on-chip (Figure 5A).
An advantage of this in vivo mouse model system is that 4T1 and
4T07 tumour cells are resistant to treatment with 6-Thioguanine (6-
TG)40. Thus, to confirm whether cells captured by the SB microfilter
device originated from their primary tumours, viable cells were
mechanically released by physical separation of the SB microfilter
layers, placed in 96-well plates in triplicate, and grown in the
presence of RPMI culture media supplemented with 50 mM 6-TG
(Sigma-Aldrich, St Louis MO) for 5 days. After drug treatment, cell
viability was assessed using the CellTiter Blue assay (Promega,
Madison WI) where viable cells reduce resazurin to resourufin,
which produces a fluorescent signal that can be detected by a plate
reader at 590 nm. In contrast to SKBR-3 breast cancer cells that
demonstrate sensitivity to 6-TG treatment, primary tumours and
corresponding CTCs from 4T1 and 4T07 cells show similar
viability in the presence of 6-TG compared to untreated controls
(Figure 5B). Further, the execution of this experiment demon-
strates the ability to release cells from the SB microfilter with
efficiency and successfully culture tumour cells on surfaces other
than the parylene-C membrane.
After establishing that our device captured CTCs that originated
from 4T1 and 4T07 primary tumours, we injected 13 104 4T1 CTCs,
4T07 CTCs, and their respective corresponding parental cell lines as
positive controls, into the mammary fat pad (FP; n 5 5 each) of
BALB/C mice. Tumours were allowed to form in all groups injected
FP for 20 days, when they were sacrificed, primary tumour was
removed and prepared for histological analysis as described above.
As shown in Figure 5C, tumours were established in 100% (20/20) of
mice with no discernable differences in the tumour volume and rate
of growth between viable CTCs recovered by the SB microfilter
device and that of their corresponding parental cell lines (data not
shown), demonstrating similar tumourigenicity. Further studies on
themouse CTCs derived animal models are currently underway, and
will be reported separately.
In our studies, 0.4–0.6 mL whole mouse blood was drawn from
each mouse by submandibular cheek puncture for viable CTC
enrichment. Using the same procedure, the SBmicrofilter can enrich
CTCs from ,0.1 mL whole mouse blood, which is a safe blood
volume that can be drawn from adult mice repetitively (e.g. weekly).
This will enable CTC studies inmouse models of metastasis, which is
critically important to improve our current understanding of the
overall metastatic process.
Clinical sample testing with SB microfilter. We investigated the
feasibility of using the current 1 cm2 SB microfilter for CTC
Figure 4 | On-chip cell proliferation demonstrated with various cell lines (DU145, Hela, LnCaP and PC3). The images in each column are bright field
microscopic images of cell growth on Petri dish as positive control and day 0, 4, and 8 on SB microfilters after enrichment.
www.nature.com/scientificreports
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enrichment from clinical blood samples. One mL whole blood from
each metastatic colorectal cancer patients was applied to the device.
After enrichment, on-chip cocktail immunocytochemical staining
for CK 8/18/19 (red), CD-45 (green, pseudo-colour) and DAPI
(blue) were used to positively and negatively select CTCs and non-
tumour, nucleated blood cells, respectively. One example is shown in
Supplementary data (Figure S1), where a CTC (CK1/CD452/
DAPI1) was captured and detected on the edge of the pore on top
parylene-C membrane, while smaller leukocytes (CK2/CD451/
DAPI1) were trapped between the top and bottom parylene-C
layers. For a 1 cm2 device, the practical blood sample capacity was
limited to ,1.5 mL. It is worth noting that, while the current SB
microfilter device is capable of processing a whole tube of fresh blood
of 7.5 mL, it takes much longer and has a higher risk of clogging the
device (Supplementary data, Figures S2 and S3). Also for 7.5 mL
whole blood, the captured cells are too crowded to maintain cancer
cell morphology, which might prevent further analysis.
Discussion
One challenge of cell surface antigen dependent CTC enrichment is
that CTCs in clinical blood samples are highly heterogeneous in
surface antigen expression, and the EpCAM-based approach only
selects for CTC subpopulations with high EpCAM expression.
Further, EpCAM expression is absent from,15–30% solid tumours
and down-regulated in many CTCs, especially those believed to have
undergone epithelial-mesenchymal transition (EMT) or those har-
bouring stem/progenitor phenotypes41–44. Independent of surface
antigen expression, size-based enrichment is a particularly attractive
approach based on the observation that malignant tumour cells are
characteristically larger and less deformable than most of the non-
tumour blood cell counterparts45,46. Importantly, this allows the
potential to isolate a more heterogeneous population of CTCs.
Caution should be exercised in this approach, as with any other
enrichment methods, since small CTCs in clinical samples their
significance are still under investigation17.
Previously we designed various microfabricated filtration devices
for size-based CTC enrichment applications. One of the most recent
viable CTC enrichment devices, the 3D microfilter, has two layers of
integrated parylene-C membranes, with 9 and 8 mm diameter una-
ligned pores on the top and bottom parylene-C membranes, respect-
ively37. Tumour cells are larger than blood cells and captured inside
the top pore, while blood cells can penetrate the top pores, gaps
between the top and bottommembranes and then the bottom pores.
The device was demonstrated to capture viable tumour cells.
Figure 5 | In vivo study of tumourigenicity of 4T1 and 4T07 CTCs in mouse models. (A): 4T07 and 4T1 viable CTCs captured by the bilayer microfilter
device on-chip 21 days after their enrichment from whole blood, and their corresponding primary tumours in culture. In both tumour types, CTCs were
found inside the central pore as well as around the central pore and in themargins of the bilayer membrane device, indicating their ability tomigrate away
from the original site capture. (B): Fluorescent intensities of primary tumour cells and viable CTCs cultured in the presence of 6-TG treatment (orange)
compared to untreated controls (green). The fluorescent intensities of tumour cells with no TiterBlue reagent (blue) and 6-TG 1 culture media alone
(purple) were also measured as a control, and demonstrate that there was no auto fluorescence contributing to the signals detected in treated versus
untreated samples. (AU 5 Arbitrary Units). (C): H&E staining of FFPE sections from viable 4T1 and 4T07 CTCs captured by the SB microfilter. CTCs
injected into mammary fads of mice demonstrate the formation of poorly differentiated, invasive tumours characteristically similar to their
corresponding parental cell lines.
www.nature.com/scientificreports
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However, cells did not proliferate presumably due to the limited
space provided by the top pores (9 mm diameter) where cells were
captured and immobilized tightly without extra space.
In this study, we designed, microfabricated and characterized a
new three-dimensional microfilter for viable CTC enrichment based
on physical properties of the cells. Compared with the fabrication
process of the previous 3D microfilter37, there are several major
changes and the overall process has a much higher yield. First, the
SB microfilter was completely constructed with parylene-C, a trans-
parent and biocompatible polymer, without a silicon support as the
3Dmicrofilter. Although the device is still made on silicon substrate,
the wafer is only served as a device carrier. As a result, the SB device
fabrication process eliminates the demanding fabrication steps of
double side alignment and through wafer etching as in the 3Dmicro-
filter. Secondly, the pores on the top parylene layer have a large
diameter of 40 mm, thus CTCs are not captured inside the top pores
on the SB microfilter, but instead trapped in the gaps at the edge of
large top pores and the bottom parylene-C layer. This design spe-
cification allows greater freedom for enriched tumour cells to
expand, migrate, and proliferate on the surface of the device. The
key fabrication parameter to be controlled during fabrication is the
thickness of the sacrificial photoresist, which determines the gap
distance between the top and bottom parylene-C membranes and
can be controlled down to ,0.1 mm resolution. Another important
design characteristic of the SB microfilter is that the adhesion
between the top and bottom parylene layers are controlled during
microfabrication to make it strong enough to hold in-place during
operation, but they can be separated easily with tweezers afterwards.
The exposed cells are thus more accessible to chemicals that for
examples disrupt cell adhesion for more efficient release, stain cells
for imaging or lyse cells for genetic analysis. The critical innovations
we have made to our multilayer technology enabled us to extend the
fundamental working principles and advantages of size-based CTC
enrichment to viable cell capture and functional characterization.
We demonstrated the viability and proliferative capacity of cap-
tured cells by the SB microfilter using multiple cancer cell lines in
vitro. The efficacy of the SB microfilter device was further validated
using whole blood samples from a breast cancermousemodel system
in vivo, demonstrating our ability to capture and culture viable CTCs
from mice injected with tumour cells of varying metastatic capacity.
The SB microfilter succeeded in enrichment and in vitro culture of
CTCs from hundreds of microliters of mouse blood. Considering the
current 1 cm2 SB microfilter process whole blood volume in the
range of 0.1–1.5 mL, which perfectly fit the total bleed out volume
for adult mouse of 0.6–1.4 mL47, thus this device is a highly valuable
tool for CTC studies in pre-clinical mouse models.
In a feasibility study, the SB microfilter was shown to capture
CTCs from an unfixed metastatic cancer patient blood sample.
Since it is desirable to assess larger blood volumes (e.g. a full tube
of blood of 7.5 mL) in a clinical setting, future study will increase
sample-processing capacity by expanding the effective filtration area.
Further, the maintenance of CTC cultures from human blood sam-
ples is a more complicated task than in mouse model systems.
However, recent report on CTC culture after enrichment by CTC-
iChip demonstrated the feasibility48. In addition to viable CTC isola-
tion, the optimal culture conditions for CTC expansion will need to
be determined. An important advantage of the SB microfilter is its
ability to simultaneously act as a capture, analysis, and culture plat-
Figure 6 | Device design. (A): Each device has four large filter patches; (B): Each filter patch is an 8 by 8 array of elemental units; (C): Geometry of four
elemental units and their arrangement. A picture of an elemental unit (boxed in orange dash lines) is shown in Figure 1C.
Figure 7 | Process flow of SB microfilter device fabrication. (a) Deposition and patterning of bottom layer parylene-C; (b) Patterning of sacrificial
photoresist; (c) Deposition and patterning of top layer parylene-C; (d) Removal of residual aluminum film and sacrificial photoresist; (e) Release of
device from the substrate.
www.nature.com/scientificreports
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form, which can easily be integrated with highly efficient next-gen-
eration culture reagents49–51 in the future aiming at expanding
tumour cells in vitro from low numbers of founder cells.
Our technology provides the opportunity to perform functional
characterization of CTC beyond their enumeration, a critical step
towards a better understanding of the mechanisms underlying CTC
release, haematogenous spread, and colonization of distant sites.
Such studies will be critical in elucidating functionally important
tumour cell subsets and tumorigenic CTCs for improved patient
management. The further development of technologies aimed at
functional CTC characterization could have profound implications
on the basic and translational study of cancer, such as the establish-
ment of in vivo models for metastasis that more closely resemble
disease while in transit to secondary sites. Further, the in vitromain-
tenance of viable CTC enriched from cancer patients could permit
the development of drug sensitivity assays, such that an assessment
can be made to predict whether a course of adjuvant therapy is
suitable for a patient before treatment begins, monitor the efficacy
of an on-going treatment in real-time, as well as potentially expose
novel mechanisms for resistance to a given therapy. Our work could
be the basis to reliably establish CTC cultures from human patients
and provide a transformative approach to the functional character-
ization of CTCs, leading to exciting new avenues for improved
patient management and cancer research.
Methods
Device design. A device is composed of a 2 by 2 array of filter patches (Figure 6A).
Each patch is an 8 by 8 array of the elemental units (Figure 6B). Each elemental unit is
530 mmby 530 mmin dimension. An element unit is separated from its neighbours by
50 mm (Figure 6C). These 50 mm borders are where the top and bottom parylene-C
layers adhere to each other. The gap between the top and bottom parylene-C
membranes can be precisely defined (5.5 mm in the current device) by the thickness of
the sacrificial photoresist. The bottom layer contains the 8 mm diameter holes
arranged hexagonally. The centre-to-centre distance of the 8 mm diameter holes is
25 mm. Larger holes of 40 mmdiameter are created on the top layer and aligned to the
centres of the corresponding hexagon patterns on the bottom layer.
Fabrication process. Figure 7 illustrates the process flow of the device fabrication. It
began with surface treatment of a single side 6-inch wafer with oxygen plasma. The
first layer of 10 mm-thick parylene-C was deposited subsequently. A thin layer of
aluminum was thermally evaporated and patterned with lithography and aluminum
etchant type D. Parylene-C was etched with oxygen plasma with the aluminum as the
mask. A 5.5 mm-thick SPR 955 photoresist was spin-coated after dissolving the
aluminum mask with aluminum etchant. The photoresist was patterned with
photolithography and serves as the sacrificial layer, which defined the gap between
the top and the bottom parylene-C layers. A second layer of 10 mm-thick parylene-C
was deposited. Prior to the deposition for the second layer of parylene-C, the exposed
area of the first layer parylene-C was treated with oxygen plasma. Another layer of
aluminum was thermally deposited and patterned with photolithography and
aluminum etchant. The top parylene-C was patterned with oxygen plasma, after
which the aluminum mask was dissolved again with aluminum etchant. The
sacrificial photoresist was dissolved with acetone and rinsed with isopropyl alcohol
and deionized water. Finally the device was released from the substrate.
Filtration assembly and process. After device fabrication, it was assembled into a
device housing, which was similar to our previous reports38,46. During filtration the SB
microfilter was secured between two sealing O-rings formed from
polydimethylsiloxane (PDMS; DOW Corning) and clamped inside of a plastic
housing cassette. The top piece of the housing cassette connected to a sample-loading
syringe while the bottom piece of the housing cassette included a luer adapter for
integration with a waste trap (Figure 8). This housing assembly acted as a reliable
support for the SB microfilter and eliminates the possibility of fluid leakage. Blood
samples were passed through the SB microfilter under gravity flow.
Cell culture.Human breast cancer cell linesMCF-7 andMDA-MB 231were cultured
in high glucose DMEM or RPMI-1640 base medium. LNCaP were cultured in RPMI-
1640 culture medium. DU-145 and HeLa cells were cultured in EMEM culture
medium. Human prostate cancer cell line PC-3 was cultured in F-12K culture
medium. The base media were supplemented with 10% fetal bovine serum (FBS), 100
units/mL penicillin and 100 mg/mL streptomycin (Invitrogen, Carlsbad CA) in
humidified incubators at 5% CO2 and 37uC ambient temperature. At 70–80%
confluency, cells were harvested from culture flasks by incubation with 0.25%
Trypsin-EDTA (Invitrogen Carlsbad CA), washed in 1 3 Dulbecco’s phosphate
buffered saline (1 3 DPBS; Invitrogen, Carlsbad CA), and used for use in subsequent
experiments described below.
Collection of blood samples.Healthy blood was obtained from consented donors at
the Penn State General Clinical Research Centre according to an Institutional Review
Board (IRB) approved protocol. Samples were drawn into EDTA-coated vacutainer
tubes (Becton Dickinson, Franklin Lakes, NJ) from peripheral venepuncture. Blood
samples were processed immediately upon receipt to facilitate optimal filtration
conditions.
Capture efficiency measurement. Harvested MCF-7 and MDA-MB-231 breast
cancer cells were incubated with acridine orange (Invitrogen Carlsbad CA) at room
temperature for 5 minutes. The tumour cells were then washed three times in 1 3
DPBS, placed on 96-well plates and counted. One mL of appropriately diluted tumour
cells were spiked into 1 mLof undiluted healthy human blood and passed through the
SB microfilter. After filtration the device was washed with 1 mL of DPBS. The SB
microfilters were observed under a fluorescencemicroscope to determine the number
of captured tumour cells.
Measurement of tumour cell enrichment against leukocytes. The enrichment
factor is defined as the ratio of tumour cells to leukocytes left on the filter after
filtration divided by that before filtration. Assuming perfect CTC capture efficiency,
the enrichment can be simplified as the ratio of the number of leukocytes in the blood
sample before filtration to the number of leukocytes remaining on the device after
filtration. To measure enrichment, 1 mL of undiluted blood was passed through the
SB microfilter with the same conditions described above for capture efficiency. The
devices were washed with 1 3 DPBS immediately after filtration and fixed with 4%
paraformaldehyde (VWR) for 20 minutes. 1 mg/mL of 49, 6-diamidino-2-
phenylindole (DAPI; Invitrogen, Carlsbad CA) was used for nuclear visualization.
The devices were observed under a fluorescence microscope and imaged at various
locations on the device at 10 3 magnification. A threshold was set based on
fluorescence intensity. Acquired images were then processed using ImageJ (National
Institute of Health, Bethesda MD) to enumerate nucleated cells.
Cell viability assay.MCF-7 andMDA-MB-231 breast cancer cells were diluted in 13
DPBS on 96-well plates and counted. 150 cells were spiked into 1 mL of DPBS and
passed through the SBmicrofilter. After filtration the devices were washed with 1 mL
1 3 DPBS and stained with the LIVE/DEAD cell assay (Invitrogen, Carlsbad CA)
where viable cells are reactive with Calcein-AM green (8 mM) and non-viable,
apoptotic or dead cells are reactive with Ethidium Homodimer-1 (EthD-1, 4 mM).
Captured cells were observed directly on the SB microfilter devices under a
fluorescencemicroscope to determine the number of viable cells that were positive for
Calcein-AM reactivity (green) and negative for Ethidium Homodimer-1 (red).
Figure 8 | Filtration setup including device housing.
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Virus infection assay for cell viability. The microfilters were washed with DPBS
immediately after filtration and transferred into a 6-well plate containing 1.5 mL of
DMEM medium. 100 mL DMEM medium was added to the top chamber formed
between the sealing o-ring and the microfilters. The captured tumour cells were
immediately infected with 107 pfu/mL recombinant adenoviruses Ad5GDE3, where
in wild-type adenoviruses the dispensable E3 gene was replaced with a CMV-eGFP
expression cassette. Captured tumour cells were incubated for 24 hours in humidified
incubators at 37uC with 5% CO2 to allow virus infection and GFP expression.
Cell proliferability after enrichment. DU145, Hela, LnCaP and PC3 cells were
appropriately diluted and spiked into DPBS with final concentration of,103 per mL,
respectively, and passed through the SB microfilter as described above. The SB
microfilters were then transferred into different wells of a six-well plate and cultured
directly on the surface of the device as described above.
In vivo animal model systems. Immunocompetent, Balb/C mice (n 5 6) were
injected into the mammary fat pad with 1 3 104 4T1 (n 5 3) or 4T07 (n 5 3) mouse
mammary tumour cells possessing high metastatic and poor metastatic potential,
respectively. Both mouse tumour cells lines are derived from the same spontaneously
arising mammary tumour from Balb/cfC3H mice. At 25 days, the mice were
sacrificed, and primary tumours were surgically resected. Half of each primary
tumour was digested in 200 units/mL of collagenase IV (Invitrogen, Carlsbad CA)
and placed into T75 flasks with RPMI at 37uC for culture, while the other half of
primary tumours were fixed in 10% neutral buffered formalin for .24 hours and
embedded in paraffin for immunohistochemical/immunofluorescent (IHC/IF)
analyses. To confirm the presence of tumour growth in the mammary fat pad, 5 mm
FFPE sections were prepared using a microtome, mounted onto glass microscope
slides and baked overnight at 57uC. The tissue sections were then deparrafinized in
xylene for 10 minutes, rehydrated with washes in decreasing concentrations of
alcohol (100%, 90%, and 70%, for 5 minutes each), briefly rinsed with water,
incubated in CAT Hematoxylin (Biocare Medical, Concord CA) for 4 minutes,
briefly rinsed with water, incubated in Tacha’s Bluing Solution (Biocare Medical,
Concord CA), dipped 10 times in Eosin-Y (Richard Allan Scientific, Kalamazoo MI),
dehydrated with washes in increasing concentrations of alcohol (70%, 90%, 100%, for
5 minutes each), incubated in xylene for 5 minutes, then coverslipped using
mounting medium (Richard Allan Scientific, Kalamazoo MI). Approximately 0.4–
0.6 mL whole blood was drawn from each mouse by submandibular cheek puncture
into 1.5 mL Eppendorf tubes containing 25 units sodium heparin (Sigma-Aldrich, St
Louis, MO) in HBSS. Whole blood samples were immediately diluted to a final
volume of 5 mL in 13Hank’s balanced salt solution (13HBSS; Invitrogen, Carlsbad
CA) and processed by the SB microfilter device as described above. Successfully
established tumour cell cultures from primary tumours and corresponding CTCs
were further characterized by molecular and functional analyses.
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